http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7cacd17e72bc978d583262d6f9ad739f
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Ashworth |
| name | Alan Ashworth |
| given-name | Alan |
| organization-name | The Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom; Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, 8The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research Fulham Road London SW3 6JB UK 1Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, UK. 1CRUK Gene Function Laboratory, Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 2Academic Department of Biochemistry, and 3Breast Unit, Royal Marsden Hospital, London, United Kingdom The Breakthrough Breast Cancer Research Centre at The Institute of Cancer Research 2 , Fulham Road, London SW3 6JB, UK Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK, Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, UK. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research; 2Cardiovascular Division, King's College London, British Heart Foundation Centre for Research Excellence, James Black Centre; and 3Division of Molecular Biosciences, Imperial College London, London, United Kingdom The Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, United Kingdom and Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital; 3Breakthrough Breast Cancer Research Unit, King's College London School of Medicine, Guy's Hospital, London, United Kingdom Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; and 2Breast Unit, Royal Marsden Hospital, London, United Kingdom 1The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK.; 2The Breast Cancer Now Toby Robins Breast Cancer Research Centre, London, UK. 1Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom.; 2Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom. Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research London United Kingdom The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK the Breakthrough Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research 237 Fulham Road London SW3 6JB UK Breakthrough Breast Cancer Research Centre, London, United Kingdom; and Cancer Research Campaign Centre for Cell and Molecular Biology and Section of Gene Function and Regulation, Chester Beatty Laboratories, The Institute of Cancer Research, Fulham Road, London SW3 6JB, United Kingdom; and Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN, United Kingdom The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, U.K. UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, CA, USA 4The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom 1The CRUK Gene Function Laboratory and The Breast Cancer Now Toby Robins Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; Departments of From the Drug Development Unit, Royal Marsden National Health Service Foundation Trust; The Institute of Cancer Research, Sutton, Surrey; Institute of Genetics and Molecular Medicine, University of Edinburgh Cancer Research, Edinburgh; the Breakthrough Breast Cancer Research Unit at King's College London, Guy's Campus; the Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London; AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; the Netherlands Cancer... Authors' Affiliation: The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California 94158, United States; Department of Medicine, University of California, San Francisco, California 94158, United States 2Cancer Research UK, Breakthrough Breast Cancer Research Centre; Authors' Affiliations: 1Section of Paediatric Oncology, The Institute of Cancer Research, and 2Paediatric Oncology, Royal Marsden Hospital, Sutton, United Kingdom; 3Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, and 4Breakthrough Breast Cancer Unit and 5Clinical Neuropathology, Kings College Hospital, London, United Kingdom; 6Life and Health Sciences Research Institute, University do Minho, Braga, Portugal; 7Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal; and 8St Jude Children's Research Hospital, Memphis, Tennessee The Breakthrough Breast Cancer Research Centre, 237 Fulham Road, London, UK. Chester Beatty Laboratories, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK. 1The CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom.; 2Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. Authors' Affiliations: 1Cancer Research UK Gene Function and Regulation Group, 2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Authors' Affiliations: 1Cancer Research UK Gene Function and Regulation Group, 2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital, London, United Kingdom; 3Department of Oncology, Merck Research Laboratories, Boston, Massachusetts; and 4Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, Texas The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London SW3 6JB, U.K. 2Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 2Department of Gynaecologic Oncology, Royal Marsden Hospital NHS Foundation Trust, 3Department of Biostatistics and 4Department of Histopathology, Royal Marsden Hospital; 5Department of Histopathology, Imperial College London, Hammersmith Hospital; and 6Ovarian Cancer Action Research Centre, Imperial College London, Hammersmith Campus, London, United Kingdom; 7University of Edinburgh Cancer Research Centre, Edinburgh; United Kingdom; 8Department of Pathology, Belfast Health and Social Care Trust; 9Department of Oncology, Belfast Health and Social Care Trust, Belfast, United Kingdom University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research Fulham Road London SW3 6JB UK Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.; 2Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom. 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom and Division of Breast Cancer Research (M.R., E.J.F., M.D., A.A., A.J.S.), Sutton SM2 5NG and London SW3 6JB, United Kingdom;; Breakthrough Breast Cancer Research Centre (M.D., A.A.), Sutton SM2 5NG and London SW3 6JB, United Kingdom;; Division of Molecular Pathology (M.D., A.A.), The Institute of Cancer Research, University of London, Sutton SM2 5NG and London SW3 6JB, United Kingdom; 1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; 2Department of Medicine, Division of Hematology/Oncology, University of California, San Francisco, San Francisco, California. 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; The Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK; Current Address: UCSF Helen Diller Family Comprehensive Cancer Centre, San Francisco, California, USA Section of Gene Function and Regulation Cancer Research UK Gene Function and Regulation Group, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK The Breakthrough Breast Cancer Research Centre; The Institute of Cancer Research; 237 Fulham Road, London SW3 6JB UK; Cancer Research UK Gene Function Laboratory; The Institute of Cancer Research; 237 Fulham Road, London SW3 6JB UK Breakthrough Breast Cancer Research Centre Institute of Cancer Research London UK Authors' Affiliations: 1Cancer Research UK Gene Function and Regulation Group and 2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Authors' Affiliations: 1Cancer Research UK Gene Function and Regulation Group and 2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom the National Heart and Lung Institute (Cardiac Medicine), Imperial College of Science, Technology, and Medicine, and the Section of Cell and Molecular Biology, Chester Beatty Laboratories, Institute of Cancer Research, University of London (UK). Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; and 2Pathology Department and 3Breast Unit, Royal Marsden Hospital, London, United Kingdom Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW7 3RP, United Kingdom Breakthrough Breast Cancer Research Centre and Division of Breast Cancer Research. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, United Kingdom Cancer Research UK Gene Function and Regulation Group; London UK; Cancer Research UK Gene Function and Regulation Group; London UK 12UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW7 3RP, U.K. The Breakthrough Breast Cancer Research Centre Institute of Cancer Research London UK; The CRUK Gene Function Laboratory Institute of Cancer Research London UK University of California, San Francisco, Helen Diller Comprehensive Cancer Center, San Francisco, CA UCSF Helen Diller Family Comprehensive Cancer Center San Francisco CA USA Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, Institute of Cancer Research, London SW3 6JB, United Kingdom 14Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California.; 14Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California. Authors' Affiliations: 1Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; 2The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research; 3Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, London, United Kingdom; 4Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, School of Population Health and 5Department of Pathology, The University of Melbourne; 6Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab), Research Division, Peter MacCallumCancer Center; 7Cancer Epidemiology Centre, Cancer Council Victoria; 8The Alfred Hospital, Melbourne, Victoria, Australia; Departments of 9Epidemiology and 10Molecular Pathology, The Netherlands Cancer Institute - The Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; 11Warwick Medical School, Warwick University, Coventry, United Kingdom; 12Departm The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, SW3 6JB London, UK. Authors' Affiliations: 1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research; 2Breast Unit, Royal Marsden Hospital, London; 3Institute of Cancer Therapeutics, University of Bradford, Bradford; and 4Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Leeds, United Kingdom UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. UCSF Helen Diller Family Comprehensive Cancer Center; San Francisco CA USA The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, United Kingdom; Authors' Affiliations: 1The CRUK Gene Function Laboratory, 2Functional Genomics Laboratory, Breakthrough Breast Cancer Research Centre, and 3Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom 1Breakthrough Breast Cancer Research Centre, Institute of Cancer Research and 21 Division of Breast Cancer Research; 22 Breakthrough Breast Cancer Research Centre and; 23 Division of Molecular Pathology, The Institute of Cancer Research, London, UK The CRUK Gene Function Laboratory and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, UK Department of Anaesthesia, University Hospital of South Manchester, Wythenshawe Hospital, Manchester M23 9LT 3UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California. 2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; and Authors' Affiliations: 1The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; 2Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; 3The Cancer Research UK Gene Function Laboratory; 4Breakthrough Breast Cancer Research Center; 5Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; 6University of California San Francisco, San Francisco, California; 7Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; 8The Chaim Sheba Medical Center, Tel Hashomer, Israel; 9Princess Margaret Hospital, Toronto, Canada; 10Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and 11Dana Farber Cancer Center, Boston, Massachusetts; Authors' Affiliations: 1The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton; 2Edinburgh Cancer Research UK Center, Medical Research Council Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh; 3The Cancer Research UK Gene Function Laboratory; 4Breakthrough Breast Cancer Research Center; 5Tumour Profiling Unit, The Institute of Cancer Research, London, United Kingdom; 6University of California San Francisco, San Francisco, California; 7Department of Medical Oncology, Prince of Wales Clinical School, Prince of Wales Hospital, Sydney, Australia; 8The Chaim Sheba Medical Center, Tel Hashomer, Israel; 9Princess Margaret Hospital, Toronto, Canada; 10Oncologisch Centrum Vrije Universiteit Brussel, Brussels, Belgium; and 11Dana Farber Cancer Center, Boston, Massachusetts The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK; Cancer Research UK Gene Function Laboratory, The Institute of Cancer Research, London, UK Breakthrough Breast Cancer Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom 1Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (UCSF), San Francisco, California.; 14Department of Medicine, UCSF, San Francisco, California. Airman Systems Directorate Bioeffects Division Air Force Research Laboratory 414 Petroleum Road Bldg. 3260 Fort Sam Houston TX 78234 Authors' Affiliations: The Breakthrough Breast Cancer Research Centre, Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom From the Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom 2Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, United Kingdom; and Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research 237 Fulham Road London SW3 6JB UK Alan Ashworth is president of the Helen Diller Family Comprehensive Cancer Center and senior vice president for cancer services at UCSF Health. Division of Breast Cancer Research The Institute of Cancer Research London United Kingdom; Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research London United Kingdom; Division of Molecular Pathology The Institute of Cancer Research London United Kingdom 1Cancer Research UK Gene Function and Regulation Group and; 2The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; The Breakthrough Breast Cancer Research Centre The Institute of Cancer Research London UK 3Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, University of London; 3Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. 2Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, England, UK Authors' Affiliations: 1Experimental Oncology, Department of Oncology and 2Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada; 3Pharmaceutical Sciences Division, Department of Pharmacognosy, National Research Centre, Dokki, Giza, Egypt; 4The Breakthrough Breast Cancer Research Center; and 5CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom; Authors' Affiliations: 1Experimental Oncology, Department of Oncology and 2Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta, Canada; 3Pharmaceutical Sciences Division, Department of Pharmacognosy, National Research Centre, Dokki, Giza, Egypt; 4The Breakthrough Breast Cancer Research Center; and 5CRUK Gene Function Laboratory, The Institute of Cancer Research, London, United Kingdom The Breakthrough Breast Cancer Research Centre, London, United Kingdom The authors are at The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK. Authors' Affiliations: 1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil; Authors' Affiliations: 1Divisions of Molecular Pathology and 2Cancer Therapeutics, and 3Breakthrough Breast Cancer Research Centre and CRUK Gene Function Laboratory, Division of Breast Cancer Research, The Institute of Cancer Research; 4Royal Veterinary College; 5Great Ormond Street Hospital, London, United Kingdom; 6University of Coimbra, Coimbra; 7ICVS, University of Minho, Braga, Portugal; and 8Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos SP, Brazil The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research 237 Fulham Road London SW3 6JB UK Department of Human Genetics Genome Institute of Singapore Singapore Singapore Helen Diller Family Comprehensive Cancer Center, University of California San Francisco (UCSF) , San Francisco, CA, USA; Department of Medicine, Division of Hematology/Oncology, UCSF , San Francisco, CA, USA 3Breakthrough Breast Cancer Research Centre, Institute of Cancer Research; 2The Institute of Cancer Research, London, United Kingdom. The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK; CRUK Gene Function Laboratory, The Institute of Cancer Research, London, UK 1The Breakthrough Breast Cancer Research Centre and Authors' Affiliations: 1BioMarin Pharmaceutical Inc., Novato, California; 2Cancer Research UK Gene Function Laboratory; and 3The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Authors' Affiliations: 1BioMarin Pharmaceutical Inc., Novato, California; 2Cancer Research UK Gene Function Laboratory; and 3The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom |
Incoming Links
Total number of triples: 553.